Tags

Type your tag names separated by a space and hit enter

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis.
Med Clin (Barc). 2021 Jun 18 [Online ahead of print]MC

Abstract

BACKGROUND

The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial.

METHODS

Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group"), matched by age, comorbidities, time from symptoms onset and baseline SpO2/FiO2 ratio with 47 patients receiving standard of care alone ("SoC group").

RESULTS

There were no significant differences between the TCZ and SoC groups in the rate of clinical improvement (hospital discharge and/or a decrease of ≥2 points on a six-point ordinal scale) by day 7 (51.1% [24/47] versus 48.9% [23/47]; P-value=1.000). No differences were observed at day 14 in terms of clinical improvement (72.3% versus 76.6%; P-value=0.791), all-cause mortality (10.6% versus 12.8%; P-value=1.000), and the composite of invasive mechanical ventilation and/or death (25.5% versus 23.4%; P-value=1.000) either. Patients in the TCZ group had a more rapid normalization of C-reactive protein levels.

CONCLUSIONS

No apparent benefit was observed in patients with severe COVID-19 treated with tocilizumab as compared to a matched retrospective cohort.

Authors+Show Affiliations

Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain. Electronic address: mario_fdezruiz@yahoo.es.Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain.Unit of Infectious Diseases, Hospital Universitario "12 de Octubre", Instituto de Investigación Sanitaria Hospital "12 de Octubre" (imas12), Madrid, Spain; Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.No affiliation info available

Pub Type(s)

Case Reports

Language

eng spa

PubMed ID

34243954

Citation

Fernández-Ruiz, Mario, et al. "Tocilizumab Therapy in SARS-CoV-2 Pneumonia: a Matched Retrospective Cohort Analysis." Medicina Clinica, 2021.
Fernández-Ruiz M, López-Medrano F, Carretero O, et al. Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis. Med Clin (Barc). 2021.
Fernández-Ruiz, M., López-Medrano, F., Carretero, O., Parra, P., Ruiz-Merlo, T., & Aguado, J. M. (2021). Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis. Medicina Clinica. https://doi.org/10.1016/j.medcli.2021.06.014
Fernández-Ruiz M, et al. Tocilizumab Therapy in SARS-CoV-2 Pneumonia: a Matched Retrospective Cohort Analysis. Med Clin (Barc). 2021 Jun 18; PubMed PMID: 34243954.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis. AU - Fernández-Ruiz,Mario, AU - López-Medrano,Francisco, AU - Carretero,Octavio, AU - Parra,Patricia, AU - Ruiz-Merlo,Tamara, AU - Aguado,José María, AU - ,, Y1 - 2021/06/18/ PY - 2021/03/27/received PY - 2021/06/07/revised PY - 2021/06/09/accepted PY - 2021/7/10/entrez PY - 2021/7/11/pubmed PY - 2021/7/11/medline KW - COVID-19 KW - Estudio de cohortes pareadas KW - Evolución KW - Immunomodulatory therapy KW - Matched cohort study KW - Outcome KW - Tocilizumab KW - Tratamiento inmunomodulador JF - Medicina clinica JO - Med Clin (Barc) N2 - BACKGROUND: The effect of immunomodulatory therapy with tocilizumab for coronavirus disease 2019 (COVID-19) in real-life clinical practice remains controversial. METHODS: Single-center retrospective matched cohort analysis including 47 consecutive patients treated with intravenous tocilizumab for severe COVID-19 pneumonia ("TCZ group"), matched by age, comorbidities, time from symptoms onset and baseline SpO2/FiO2 ratio with 47 patients receiving standard of care alone ("SoC group"). RESULTS: There were no significant differences between the TCZ and SoC groups in the rate of clinical improvement (hospital discharge and/or a decrease of ≥2 points on a six-point ordinal scale) by day 7 (51.1% [24/47] versus 48.9% [23/47]; P-value=1.000). No differences were observed at day 14 in terms of clinical improvement (72.3% versus 76.6%; P-value=0.791), all-cause mortality (10.6% versus 12.8%; P-value=1.000), and the composite of invasive mechanical ventilation and/or death (25.5% versus 23.4%; P-value=1.000) either. Patients in the TCZ group had a more rapid normalization of C-reactive protein levels. CONCLUSIONS: No apparent benefit was observed in patients with severe COVID-19 treated with tocilizumab as compared to a matched retrospective cohort. SN - 1578-8989 UR - https://www.unboundmedicine.com/medline/citation/34243954/Tocilizumab_therapy_in_SARS-CoV-2_pneumonia:_A_matched_retrospective_cohort_analysis. L2 - http://www.elsevier.es/en/linksolver/ft/pii/S0025-7753(21)00367-5 DB - PRIME DP - Unbound Medicine ER -